IL183307A0 - Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists - Google Patents

Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists

Info

Publication number
IL183307A0
IL183307A0 IL183307A IL18330707A IL183307A0 IL 183307 A0 IL183307 A0 IL 183307A0 IL 183307 A IL183307 A IL 183307A IL 18330707 A IL18330707 A IL 18330707A IL 183307 A0 IL183307 A0 IL 183307A0
Authority
IL
Israel
Prior art keywords
hif
adenosine
cancer
receptor antagonists
mediated disorders
Prior art date
Application number
IL183307A
Other languages
English (en)
Original Assignee
King Pharmaceuticals Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev filed Critical King Pharmaceuticals Res & Dev
Publication of IL183307A0 publication Critical patent/IL183307A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL183307A 2004-11-22 2007-05-17 Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists IL183307A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63055704P 2004-11-22 2004-11-22
PCT/US2005/042551 WO2007040565A2 (fr) 2004-11-22 2005-11-22 Amelioration du traitement du cancer et de troubles medies par hif-1 au moyen d'antagonistes des recepteurs de l'adenosine a3

Publications (1)

Publication Number Publication Date
IL183307A0 true IL183307A0 (en) 2008-04-13

Family

ID=37906593

Family Applications (1)

Application Number Title Priority Date Filing Date
IL183307A IL183307A0 (en) 2004-11-22 2007-05-17 Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists

Country Status (6)

Country Link
EP (1) EP1827445A2 (fr)
JP (1) JP2008520746A (fr)
AU (1) AU2005336924A1 (fr)
CA (1) CA2586420A1 (fr)
IL (1) IL183307A0 (fr)
WO (1) WO2007040565A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX242553B (es) 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
ATE508747T1 (de) 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
CN101001629B (zh) 2004-09-17 2010-05-05 卫材R&D管理有限公司 药物组合物
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
WO2007136103A1 (fr) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. Agent antitumoral destiné au cancer de la thyroïde
EP2065372B1 (fr) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
KR101445892B1 (ko) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
EP2218712B1 (fr) 2007-11-09 2015-07-01 Eisai R&D Management Co., Ltd. Combinaison d'une substance antiangiogénique et d'un complexe de platine antitumoral
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
ES2538301T3 (es) * 2008-11-14 2015-06-18 Bayer Intellectual Property Gmbh Compuestos de arilo con sustituyentes heterocíclicos como inhibidores HIF
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
WO2014153363A1 (fr) * 2013-03-18 2014-09-25 Northeastern University Procédé de génération d'anticorps anti-pathogènes généralement neutralisants
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP4089076A1 (fr) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. Dérivé de quinoline à pureté élevée et son procédé de fabrication
CA2976325C (fr) 2015-02-25 2023-07-04 Eisai R&D Management Co., Ltd. Procede de suppression de l'amertume d'un derive de quinoleine
WO2016140717A1 (fr) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Association d'un antagoniste de pd-1 et d'un inhibiteur des tyrosines kinases vegfr/fgfr/ret pour traiter le cancer
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
CN114466850A (zh) 2019-08-12 2022-05-10 拜耳股份有限公司 [1,2,4]三唑并[1,5-c]喹唑啉-5-胺
WO2022029063A1 (fr) 2020-08-04 2022-02-10 Bayer Aktiengesellschaft Pyrido[1,2,4]triazolo[1,5-c]pyrimidin-5-amines
CN114574580B (zh) * 2022-02-14 2022-11-29 山东大学 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326390B1 (en) * 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
US6921825B2 (en) * 1998-09-16 2005-07-26 King Pharmaceuticuals Research & Development, Inc. Adenosine A3 receptor modulators
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Also Published As

Publication number Publication date
AU2005336924A1 (en) 2007-04-12
CA2586420A1 (fr) 2007-04-12
WO2007040565A3 (fr) 2009-04-16
WO2007040565A2 (fr) 2007-04-12
JP2008520746A (ja) 2008-06-19
EP1827445A2 (fr) 2007-09-05
WO2007040565A9 (fr) 2007-07-05

Similar Documents

Publication Publication Date Title
IL183307A0 (en) Enhancing treatment of cancer and hif-1 mediated disorders with adenosine a3 receptor antagonists
IL183310A0 (en) Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
HK1210495A1 (en) Aptamer therapeutics useful in the treatment of complement-related disorders
IL179227A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL187248A0 (en) Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
EP1929291A4 (fr) Therapie par estriol pour maladie des troubles auto-immuns et neurodegeneratifs
IL207688A0 (en) Methods of treating skin disorders using an il-31ra antagonist
EP1926521A4 (fr) Dispositifs et procedes pour liberer des substances therapeutiques pour le traitement de la sinusite et d'autres troubles
EP1827391A4 (fr) Formes posologiques et procedes d'utilisation de celles-ci
ZA200806114B (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
IL214198A0 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling
PL1890684T3 (pl) Leczenie zaburzeń snu i czuwania
EP1740172A4 (fr) Inhibiteurs d'acetylcholinesterase et antagonistes de n-methyle-d-aspartate utiles dans le traitement de troubles cognitifs
IL181706A0 (en) The treatment of inflammatory disorders and pain
IL182222A0 (en) Treatment of bipolar disorders and associated symptoms
AP2715A (en) Use of imatinib to treat liver disorders and viralinfections
IL195900A0 (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
EP1751175A4 (fr) Antagonistes du recepteur de l'interleukine-1, compositions, et methodes de traitement
EP1833991A4 (fr) Peptides en trefles et methodes de traitement des troubles proliferatifs au moyen desdits peptides
EP1812009A4 (fr) Antagonistes des steroides gaba et leur utilisation dans le traitement des troubles du snc
AU2003250831A8 (en) Use of hec1 antagonists in the treatment of proliferative disorders and cancer
EP1732599A4 (fr) Utilisation d'antagonistes de l'inducteur de metalloproteinase dans la matrice extracellulaire pour le traitement de maladies associees a un angiogenese excessive
PL1644351T3 (pl) Pochodne imidazolu i ich zastosowanie w leczeniu zaburzeń mediowanych przez receptor mGluR5
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
IL182768A (en) A combination containing fluoxatin and the glucocorticoid receptor ru34850 antagonist for use in the treatment of depression or related disorder